Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVDL Avadel Pharmaceuticals	$12.75 +0.1%	$10.05	$6.38 ▼ $16.84	$1.23B	1.47	1.16 million shs	1.54 million shs
FDMT 4D Molecular Therapeutics	$5.63 -2.6%	$4.42	$2.23 ▼ $17.41	$267.76M	2.83	2.24 million shs	552,736 shs
HROW Harrow	$34.43 +3.7%	$32.44	$20.85 ▼ $59.23	$1.22B	0.41	464,528 shs	531,221 shs
PRAX Praxis Precision Medicines	$45.94 -2.8%	$48.11	$26.70 ▼ $91.83	$994.83M	2.62	543,862 shs	438,540 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVDL Avadel Pharmaceuticals	+0.08%	+15.07%	+33.51%	+35.78%	-20.81%
FDMT 4D Molecular Therapeutics	-2.60%	-12.31%	+27.38%	+82.79%	-61.73%
HROW Harrow	+3.67%	+10.25%	+8.75%	+41.11%	+56.64%
PRAX Praxis Precision Medicines	-2.81%	-15.07%	-8.49%	+19.79%	-11.70%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVDL Avadel Pharmaceuticals	2.8114 of 5 stars	3.5	2.0	3.9	1.7	0.6
FDMT 4D Molecular Therapeutics	2.5029 of 5 stars	3.3	3.0	2.3	1.7	0.6
HROW Harrow	2.4878 of 5 stars	3.5	1.0	2.9	2.5	0.6
PRAX Praxis Precision Medicines	1.6617 of 5 stars	3.4	1.0	2.4	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVDL Avadel Pharmaceuticals	3.00	Buy	$18.67	46.41% Upside
FDMT 4D Molecular Therapeutics	2.60	Moderate Buy	$29.56	424.97% Upside
HROW Harrow	3.00	Buy	$63.83	85.40% Upside
PRAX Praxis Precision Medicines	2.78	Moderate Buy	$95.22	107.28% Upside

Current Analyst Ratings Breakdown

Latest FDMT, HROW, PRAX, and AVDL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	AVDL Avadel Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $24.00
8/5/2025	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$105.00 ➝ $115.00
8/1/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/29/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
7/29/2025	PRAX Praxis Precision Medicines	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
7/18/2025	AVDL Avadel Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$22.00
7/18/2025	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$105.00
7/12/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
7/11/2025	HROW Harrow	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$76.00
7/8/2025	PRAX Praxis Precision Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$97.00 ➝ $115.00
7/3/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00

(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVDL Avadel Pharmaceuticals	$169.12M	7.29	N/A	N/A	$0.77 per share	16.56
FDMT 4D Molecular Therapeutics	$40K	6,520.95	N/A	N/A	$11.05 per share	0.51
HROW Harrow	$199.61M	6.33	$0.14 per share	242.87	$1.95 per share	17.66
PRAX Praxis Precision Medicines	$8.55M	113.10	N/A	N/A	$19.21 per share	2.39

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVDL Avadel Pharmaceuticals	-$48.83M	-$0.27	N/A	212.50	N/A	-1.32%	-3.94%	-1.79%	N/A
FDMT 4D Molecular Therapeutics	-$160.87M	-$3.18	N/A	N/A	N/A	-767,126.06%	-33.26%	-30.68%	8/14/2025 (Estimated)
HROW Harrow	-$17.48M	-$0.56	N/A	86.08	N/A	-10.19%	-25.01%	-4.27%	8/11/2025 (Estimated)
PRAX Praxis Precision Medicines	-$182.82M	-$12.29	N/A	N/A	N/A	-2,137.48%	-60.07%	-54.84%	N/A

Latest FDMT, HROW, PRAX, and AVDL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	FDMT 4D Molecular Therapeutics	-$0.6922	N/A	N/A	N/A	$0.52 million	N/A
8/12/2025	Q2 2025 & Study Result	PRAX Praxis Precision Medicines	-$3.40	N/A	N/A	N/A	$0.16 million	N/A
8/11/2025	Q2 2025	HROW Harrow	$0.01	N/A	N/A	N/A	$64.23 million	N/A
8/7/2025	Q2 2025	AVDL Avadel Pharmaceuticals	$0.02	$0.10	+$0.08	$0.10	$60.28 million	$68.13 million
8/4/2025	Q2 2025 & Study Result	PRAX Praxis Precision Medicines	-$3.40	-$3.31	+$0.09	-$3.31	$0.15 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
HROW Harrow	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVDL Avadel Pharmaceuticals	N/A	2.73	2.33
FDMT 4D Molecular Therapeutics	N/A	12.36	12.36
HROW Harrow	2.01	0.91	0.85
PRAX Praxis Precision Medicines	N/A	6.31	8.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVDL Avadel Pharmaceuticals	69.19%
FDMT 4D Molecular Therapeutics	99.27%
HROW Harrow	72.76%
PRAX Praxis Precision Medicines	67.84%

Insider Ownership

Company	Insider Ownership
AVDL Avadel Pharmaceuticals	5.20%
FDMT 4D Molecular Therapeutics	9.60%
HROW Harrow	15.16%
PRAX Praxis Precision Medicines	2.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVDL Avadel Pharmaceuticals	70	96.74 million	91.71 million	Optionable
FDMT 4D Molecular Therapeutics	120	46.33 million	41.88 million	Optionable
HROW Harrow	180	36.69 million	31.12 million	Optionable
PRAX Praxis Precision Medicines	110	21.05 million	20.48 million	Optionable

FDMT, HROW, PRAX, and AVDL Headlines

Recent News About These Companies

Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine

5 hours ago | theglobeandmail.com

Research Analysts Issue Forecasts for PRAX Q3 Earnings

August 8 at 8:25 AM | marketbeat.com

What is HC Wainwright's Estimate for PRAX FY2029 Earnings?

August 7 at 8:12 AM | marketbeat.com

Wedbush Issues Negative Estimate for PRAX Earnings

August 7 at 6:46 AM | marketbeat.com

Wedbush Has Negative Outlook for PRAX Q3 Earnings

August 7 at 2:07 AM | americanbankingnews.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX

August 6 at 6:40 PM | prnewswire.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Praxis Precision Medicines (PRAX) and Pfizer (PFE)

August 6 at 6:32 PM | theglobeandmail.com

Praxis Precision Medicines (NASDAQ:PRAX) Shares Down 8.1% - Here's Why

August 6 at 5:29 PM | marketbeat.com

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 6 at 5:13 PM | gurufocus.com

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 6 at 4:01 PM | globenewswire.com

Praxis Precision Medicines (PRAX) Projected to Post Earnings on Tuesday

August 6 at 9:55 AM | marketbeat.com

HC Wainwright Forecasts Strong Price Appreciation for Praxis Precision Medicines (NASDAQ:PRAX) Stock

August 6 at 8:09 AM | marketbeat.com

Praxis Precision Medicines First Half 2025 Earnings: US$6.60 loss per share (vs US$4.58 loss in 1H 2024)

August 5, 2025 | finance.yahoo.com

Praxis’ Seizure Drug Demonstrates ‘Impressive’ Efficacy in Mid-Stage Trial

August 5, 2025 | biospace.comB

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

August 5, 2025 | globenewswire.com

Praxis Precision Medicines, Inc. Investors: Company Investigated by the Portnoy Law Firm

August 5, 2025 | globenewswire.com

Praxis Precision Medicines (NASDAQ:PRAX) Shares Gap Down - Time to Sell?

August 5, 2025 | marketbeat.com

Praxis Precision Medicines (NASDAQ:PRAX) Posts Earnings Results, Beats Expectations By $0.09 EPS

August 5, 2025 | marketbeat.com

Praxis’ vormatrigine eliminates seizures in 22% of patients in Phase II trial

August 5, 2025 | clinicaltrialsarena.comC

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

August 4, 2025 | globenewswire.com

Praxis (PRAX) Q2 Loss Widens 90%

August 4, 2025 | aol.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

FDMT, HROW, PRAX, and AVDL Company Descriptions

Avadel Pharmaceuticals NASDAQ:AVDL

$12.75 +0.01 (+0.08%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$12.46 -0.29 (-2.24%)

As of 08/8/2025 07:28 PM Eastern

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

4D Molecular Therapeutics NASDAQ:FDMT

$5.63 -0.15 (-2.60%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$5.60 -0.03 (-0.53%)

As of 08/8/2025 07:59 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Harrow NASDAQ:HROW

$34.43 +1.22 (+3.67%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$34.45 +0.02 (+0.06%)

As of 08/8/2025 07:51 PM Eastern

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Praxis Precision Medicines NASDAQ:PRAX

$45.94 -1.33 (-2.81%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$45.98 +0.05 (+0.10%)

As of 08/8/2025 04:30 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time